Novo Nordisk Q3 earnings lifted by demand for new obesity drug
.
COPENHAGEN (Reuters) – Drug developer Novo Nordisk (NYSE:NVO) on Wednesday reported third-quarter earnings lifted by strong demand for its new obesity drug.
Novo reported net profit of 12.1 billion Danish crowns ($1.88 billion) in the third quarter, an 18% increase compared to the same period last year.
($1 = 6.4217 Danish crowns)
More Stories
Oil inches higher as Middle East tensions heat up
© Reuters. Army soldier miniatures and stock graph are seen in this illustration taken October 9, 2023. REUTERS/Dado Ruvic/Illustration/File Photo...
Asian stocks rise before US CPI; Japan’s Nikkei extends rally
. JP225 +1.88% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully to: + Add another position...
SEC approves spot Bitcoin ETFs
. SEC approves spot bitcoin ETFs BTC/USD +1.76% Add to/Remove from Watchlist Add to Watchlist Add Position Position added successfully...
Google lays off hundreds in Assistant, hardware, engineering teams
© Reuters. The Google logo is seen on the Google house at CES 2024, an annual consumer electronics trade show,...
US SEC approves bitcoin ETFs in watershed for crypto market
© Reuters. FILE PHOTO: FILE PHOTO: U.S. Securities and Exchange Commission logo and representations of cryptocurrency are seen in this...
Amazon has not offered remedies to EU concerns over iRobot deal
© Reuters. FILE PHOTO: The logo of Amazon is seen at the company's logistics centre in Boves, France, October 6,...